Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Global Medical REIT Completes One-for-Five Reverse Stock Split

Global Medical REIT Inc. has completed a one-for-five reverse stock split, which became effective at 5:00 p.m. Eastern Time on September 19, 2025. This reverse stock split resulted in the conversion of every five issued and outstanding shares of common stock into one share of common stock. As a result, the company's authorized shares of common stock were reduced from 500,000,000 shares to 100,000,000 shares, and the number of shares outstanding decreased from 67,037,048 shares to approximately 13,407,409 shares.

The reverse stock split also impacted the company's stock repurchase program, equity incentive plan, outstanding equity awards, and outstanding partnership units of Global Medical REIT L.P., the company's operating partnership. Additionally, fractional shares resulting from the reverse stock split were converted to cash based on the closing price of the company's common stock on the NYSE.

Following the reverse stock split, stockholders of record will receive information from Equiniti Trust Company, the company's transfer agent, regarding their stock ownership and, if applicable, payments of cash in lieu of fractional shares. Stockholders who hold their shares in brokerage accounts or in "street name" are not required to take any action in connection with the reverse stock split.

Global Medical REIT Inc. is a net-lease medical REIT that acquires healthcare facilities and leases them to physician groups and regional and national healthcare systems. Additional information about the company can be found on its website at www.globalmedicalreit.com. The market has reacted to these announcements by moving the company's shares 2.02% to a price of $38.41. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS